Carrick Therapeutics Receives FDA Fast Track Designations for Two Samuraciclib Combinations for the Treatment of HR⁺, HER2^– Advanced Breast Cancer and Locally Advanced or Metastatic Triple Negative Breast Cancer

Carrick Therapeutics announced that the US FDA has granted Fast Track designations to samuraciclib in combination with fulvestrant for CDK4/6i resistant HR+, HER2– advanced breast cancer and samuraciclib in combination with chemotherapy for the treatment of locally advanced or metastatic TNBC.